title: Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.
abstract: The PSA screening for 25 years in America is the biggest cohort study in a field of public health.27 We should realize not only the significance of the early diagnosis and treatment of PCa, but also the dramatic decrease in PCaMR from 2002 to 2008. The data from the IARC were especially noteworthy.Moreover, the patients with highly aggressive PCa, who account for more than 30% of all PCa patients, could only be diagnosed earlier by PSA screening. The patients would thus gain the opportunity for earlier treatment and would have a prolonged, higher quality life-span. However, the complications of interventional treatments, including biopsy,radical prostatectomy and/or radiation therapy,will become more avoidable in the near future.According to the supporting evidence for the decrease in PCa mortality in PSA screening, we strongly hope that the USPSTF changes the 'D' recommendation for PSA screening.
authors: Department of Pathophysiology, Jilin University, Changchun, China.
authors: Hui-Jie
authors: HJ
authors: Jia
authors: Yang
authors: Y
authors: Li
authors: Jin-Guo
authors: JG
authors: Wang
authors: Ling
authors: L
authors: Zhang
authors: Hai-Tao
authors: HT
authors: Zhang
authors: Xue-Jian
authors: XJ
authors: Zhao
authors: Masaaki
authors: M
authors: Kuwahara
mesh_terms: D001213:Asian; D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D014481:United States / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen